Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 8/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 8/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 8/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | GCGR | P47871 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11781720 | 0.79 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6646025 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6646016 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15073410 | 0.77 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL8805646 | 0.75 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CYP19A1 | |
| SCHEMBL6643643 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5031028 | 0.73 | TUBB1 (0.78) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14270472 | 0.72 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2648503 | 0.72 | MAPK11 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL19952909 | 0.71 | MAPK13 (0.78) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2707369-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | claimed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3081568-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081568-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9427438-B2 | Compositions and methods for treating Alzheimer's disease | EIP PHARMA, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2707369-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2707369-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885 |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885 |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.